The Cigna Group (CI)
| Market Cap | 78.25B -7.3% |
| Revenue (ttm) | 277.89B +8.8% |
| Net Income | 6.29B +24.9% |
| EPS | 23.60 +31.2% |
| Shares Out | 264.53M |
| PE Ratio | 12.53 |
| Forward PE | 9.58 |
| Dividend | $6.24 (2.11%) |
| Ex-Dividend Date | Jun 4, 2026 |
| Volume | 1,472,405 |
| Open | 298.00 |
| Previous Close | 295.00 |
| Day's Range | 290.39 - 298.00 |
| 52-Week Range | 239.51 - 338.89 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 340.92 (+15.25%) |
| Earnings Date | Jul 30, 2026 |
About CI
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty p... [Read more]
Financial Performance
In 2025, The Cigna Group's revenue was $274.90 billion, an increase of 11.24% compared to the previous year's $247.12 billion. Earnings were $5.96 billion, an increase of 73.47%.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for CI stock is "Buy." The 12-month stock price target is $340.92, which is an increase of 15.25% from the latest price.
News
Volatility surge has trader eyeing one 'stable' stock
Mike Khouw is looking for a stable, cash-generating business where he can sell volatility instead of buying drama.
Cigna price target raised to $340 from $330 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on Cigna (CI) to $340 from $330 and keeps an Outperform rating on the shares. The firm believes the managed care…
Health insurer Cigna will stop covering GLP-1 weight loss drugs in its employee health plan
CNBC's Becky Quick reports on the latest news.
Exclusive: Cigna drops coverage of GLP-1 obesity drugs for its own employees
Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan effective July 1, according to materials viewe...
MJH Life Sciences® recognized with 2025 Cigna Healthy Workforce Designation™
CRANBURY, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Cigna Healthcare® has selected MJH Life Sciences® as a recipient of its 2025 gold-level Healthy Workforce Designation for demonstrating a strong commit...
BofA adds Centene to ‘US 1 List,’ removes Cigna
BofA analysts added Centene (CNC) to the firm’s “US 1 List” while removing Cigna (CI). The list is a collection of BofA’s best investment ideas.
Cigna downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Andrew Mok downgraded Cigna (CI) to Equal Weight from Overweight with a price target of $304, down from $310.
Barclays downgrades Cigna on lack of earnings catalysts
Barclays downgraded Cigna (CI) to Equal Weight from Overweight with a price target of $304, down from $310. The company has limited potential upside to earnings estimates given its low…
Cigna price target raised to $400 from $375 at UBS
UBS raised the firm’s price target on Cigna (CI) to $400 from $375 and keeps a Buy rating on the shares. Managed care organizations broadly raised guidance after stronger-than-expected Q1…
Cigna price target raised to $361 from $355 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cigna (CI) to $361 from $355 and keeps an Overweight rating on the shares after the firm hosted meetings with management that…
Cigna downgraded to Hold from Buy at Deutsche Bank
As previously reported, Deutsche Bank analyst George Hill downgraded Cigna (CI) to Hold from Buy with a price target of $302, down from $303. The company faces “multi-year uncertainty” as…
Cigna downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Cigna (CI) to Hold from Buy with a $302 price target
Easing medical costs a positive for health insurers, but real test lies ahead, analysts say
U.S. health insurers' strong first-quarter results signaled more stable medical costs after prolonged pressure, but Wall Street analysts want to see another similar quarter before they are convinced.
The Cigna Group Transcript: Bank of America Global Healthcare Conference 2026
A major transition to a rebate-free PBM model is underway, with full scaling expected by 2028 and profitability aligning with legacy models by 2029. Specialty business continues to drive growth, while AI and analytics are delivering operational efficiencies and improved patient outcomes.
The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
BLOOMFIELD, Conn., May 13, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced that Brian Evanko, President and Chief Operating Officer of The Cigna Group, will present at t...
Health Insurers Performing Better But There's Potential Trouble Ahead
Health insurance companies including UnitedHealthcare, CVS Health's Aetna, Centene and Blue Cross and Blue Shield plans owned by Elevance Health are seeing lower costs from patients submitting claims.
Cigna price target raised to $371 from $358 at Bernstein
Bernstein analyst Lance Wilkes raised the firm’s price target on Cigna (CI) to $371 from $358 and keeps an Outperform rating on the shares following quarterly results. The firm is…
Major health insurers show signs of recovery – but a key test looms
Solid first-quarter results from major insurers like UnitedHealth, Elevance, Cigna and Humana have helped lift investor sentiment, even as insurers continue to grapple with higher medical costs. But a...
Cigna price target raised to $337 from $306 at Baird
Baird raised the firm’s price target on Cigna (CI) to $337 from $306 and keeps an Outperform rating on the shares. The firm updated its model calling it an underappreciated…
Cigna price target raised to $340 from $325 at Cantor Fitzgerald
Cantor Fitzgerald analyst Sarah James raised the firm’s price target on Cigna (CI) to $340 from $325 and keeps an Overweight rating on the shares.
Cigna price target raised to $330 from $325 at Mizuho
Mizuho raised the firm’s price target on Cigna (CI) to $330 from $325 and keeps an Outperform rating on the shares.
Cigna price target raised to $310 from $303 at Barclays
Barclays raised the firm’s price target on Cigna (CI) to $310 from $303 and keeps an Overweight rating on the shares. The firm updated the company’s post the Q1 report.
Cigna is becoming the second major insurer to exit from the ACA market as millions drop coverage with the expiration of federal subsidies.
Cigna Group will exit the Affordable Care Act market next year, citing an effort to focus on other lines of business.
Cigna Plans To Exit Obamacare In 2027 Affecting 369,000 With Coverage
The Cigna Group Thursday confirmed plans to exit the individual health insurance business also known as Obamacare next year, leaving about 369,00 health plan members in 11 states looking for new cover...
The Cigna Group Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and EPS growth, prompting a raised full-year outlook. Specialty and Care Services led segment gains, while investments in the Signature model and portfolio reshaping—including exiting the individual exchange and reviewing EviCore—support future growth.